mellitus (IDDM) with a median duration of diabetes of 9.3 versus 9.0 years in the placebo group. Visual acuity remained unchanged during the entire trial. Concerning the primary endpoint, the study provided a negative result, i.e. 26/235 patients in the treatment group and 30/232 patients in the placebo group developed CSME. Confirmatory intention-totreat analysis of the primary endpoint revealed no statistically significant difference between groups (log-rank test, p = 0.7108, HR = 0.9057 with CI = 0.5355-1.5317). Median follow-up was identical (2.00 years). Conclusions: A daily dosage of 600 mg ALA does not prevent the occurrence of CSME in IDDM patients.
Introduction
Diabetic retinopathy including macular edema is the most frequent cause of blindness in Western industrialized nations [1] [2] [3] . Prevention of visual loss depends on timely detection of diabetic retinopathy and instant-laser treatment. As a timely and close glycemic control with near-normal HbA1c levels and blood pressure below 130/80 mm Hg cannot always be achieved, medical therapy to prevent the occurrence and progression of sightthreatening complications remains a challenge.
Retinal damage induced by diabetic macular edema is due to vascular leakage and nonperfusion [4] . Sustained hyperglycemia affects several vasoactive factors, notably vascular endothelial growth factor, protein kinase C and angiotensin II, all of which are interrelated and may influence the development of structural and functional changes in diabetic retinopathy [4] [5] [6] [7] [8] [9] . The upregulation of vascular endothelial growth factor is associated with a breakdown of the blood-retinal barrier and increased vascular permeability resulting in retinal edema [9, 10] . High glucose levels in endothelial cells are associated with a mitochondrial overproduction of reactive oxygen species, which inactivate glyceraldehyde-3-phosphate dehydrogenase [11] . This process plays a role in the pathogenesis of endothelial damage [12] . Therefore, antioxidants appear to be a therapeutic approach. ␣ -Lipoic acid (ALA) differs in several aspects from other antioxidants [13] [14] [15] as it distributes to mitochondria, has a very low redox potential, recycles other cellular antioxidant redox pairs (such as ascorbate) and is regenerated by hyperglycemia and nonessential fatty acid-induced nicotinamide adenine dinucleotide phosphate (via pyruvate dehydrogenase), linking the antioxidant activity to the degree of increased metabolic flux [16] .
The potential of ALA in preventing microvascular damage has been demonstrated in animals [17] . ALA has been used for years in the long-term treatment of chronic sensorial disorders in diabetic polyneuropathy at a dosage of 600 mg/day. We raised the hypothesis that a beneficial effect may also be seen in diabetic retinopathy and in the prevention of clinically significant macular edema (CSME) [18] [19] [20] [21] [22] [23] [24] .
Methods

Study Design
The RETIPON Study is a phase III, randomized, multicenter, multinational, double-blind, placebo-controlled, comparative trial to evaluate a potential effect of ALA in prolonging the time interval between the diagnosis of mild to moderate diabetic retinopathy at enrolment and the development of CSME in high-risk insulin-dependent diabetes mellitus (IDDM) patients.
The study was approved by the local ethics committee. ( table 1 ) We included outpatients, male or female, with diagnosed adult-onset IDDM, aged 45-68 years, showing mild to moderate nonproliferative diabetic retinopathy (NPDR) according to the classification of the ETDRS protocol [25] in at least one eye and presenting with microalbuminuria 1 30 mg/l as diagnosed with a urine dipstick microalbumin test (Micro-Bumintest , Bayer , Leverkusen, Germany). These patients are known to bear a high risk for microvascular complications such as CSME. Patients were insulin dependent or non-insulin dependent. Written informed consent had to be given.
Inclusion and Exclusion Criteria
Treatment Modalities and Randomization
The 600-mg dosage of ALA was established for treatment of peripheral polyneuropathy. The chemical name of the investigational drug is 1,2-dithiolane-3-valeric acid. The trial medication mg/dl or total cholesterol >320 mg/dl) -Unauthorized concomitant medications, defined as any medicine with a potential interaction with ALA or with the effect of ALA, were excluded as concomitant medications. These included aldose reductase inhibitors, substances promoting blood flow, anticoagulants apart from acetylsalicylic acid ≤500 mg/day and short-term treatment of diseases with the normal dose of acetylsalicylic acid, chronically and systemically administered corticosteroids, hormonal contraceptives -Malignancies or life-threatening diseases -Drug or alcohol abuse -Blood donation or blood loss greater than 500 ml within the last 3 months -Pregnancy or breast-feeding -Participation in a clinical trial within the last 30 days was prepared in compliance with Good Manufacturing Practice (GMP), packed and supplied by Bausch & Lomb, Berlin, Germany).
The trial medication had been granted marketing authorization and was newly packed in blister packs and relabeled as 600-mg tablets. The placebo and the drug tablets were similarly packed and labeled, and had an identical appearance and taste.
The number of tablets dispensed at the visits was recorded and subjects were instructed to return any unused medication at the next visit. All returned medications were counted to determine the actual number of tablets taken. Noncompliance was defined as an intake of less than 80% of the medication between visits.
Eligible patients accomplished a 4-week compliance test phase starting with visit 1. In case of at least 80% compliance, they were randomized at visit 2 (day 0) to receive either ALA 600-mg tablets once daily or placebo for a 24-month period. After inclusion, patients were followed at 6-month intervals.
A block design was used for randomization. Random numbers were allocated in ascending order corresponding to the order in which subjects were included after the examination on visit 2. Each patient was allocated to either active treatment or placebo using a stratified randomization within the investigation center as well as the following strata: 1 = HbA1c ! 9%, IDDM; 2 = HbA1c ! 9%, non-IDDM (NIDDM); 3 = HbA1c 6 9%, IDDM, and 4 = HbA1c 6 9%, NIDDM.
Date and time of randomization (i.e. the time point at which the current random number was allocated) were recorded for each subject. The balance of randomization was approved.
The randomization code for the trial investigational medicinal product was provided to the investigator in separate sealed envelopes (emergency envelope) labeled with trial and randomization code numbers. The breaking of the treatment code was strictly forbidden except in the event of a medical emergency. The sponsor had to be immediately notified and the reason for breaking the code documented in the subject's medical records and on the case report form. The investigator assessed the relationship of the adverse event to the trial investigational medicinal product before the treatment code was broken.
Medical Review and Physical Examination
Blood samples for laboratory tests obtained at visit 1, and 3-6 included RBC, WBC, platelet count, hemoglobin, hematocrit, GOT, GPT, ␥ -GT, creatinine, urea, uric acid, HbA1c, fasting blood glucose, total cholesterol, triglycerides. Morning urine was checked by a dipstick test for glucose, total protein, and bilirubin at visit 1 on-site. Laboratory tests were performed in a single central laboratory for all centers (MDS Pharma Services, Hamburg, Germany). Clinically relevant findings were documented in the case report form as adverse events and treated accordingly. All clinically relevant abnormal laboratory results were to be followed up until they returned to normal (i.e. to baseline), stabilized or could be explained otherwise.
At the initial visit, the patient's body weight, height, blood pressure and concomitant medication were recorded. In addition, a complete medical examination was performed. Systolic and diastolic blood pressure and pulse rate were measured at visit 1 and visits 3-6 after a 10-min rest in the supine position and recorded in the case report form. All blood pressure measurements were made on both arms using a sphygmomanometer with an appropriate cuff size for the individual subject and the mean value was calculated.
Ophthalmic Examination and Method of Macular Edema Detection
At each visit, i.e. every 6 months, patients underwent bilateral eye examination including best corrected visual acuity using the Early Treatment Diabetic Retinopathy Study (ETDRS) charts, slit lamp examination, intraocular pressure, and stereoscopic biomicroscopy. Seven-field stereo fundus photographs (in color 30°) according to the criteria of the ETDRS protocol [25] were taken. The quality of the photographs was assessed immediately upon receipt by the senior author (M.W.U.). In cases of insufficient quality, the respective center was asked to submit a new set of photographs. Fluorescein angiography at the beginning and end of the study was optional and evaluated according to the ETDRS protocol [26] . Adverse events whether or not considered to be caused by the study medication had to be reported.
Macular edema was diagnosed on stereoscopic fundus photographs according to the ETDRS protocol [26] . The fundus photographs were always evaluated by two masked examiners at the RETIPON Reading Center in Munich, Germany, under the guidance of the senior author (M.W.U.). Both graders had to concur on the final assessment and potential differences in the grading were discussed by the graders. Graders were all certified to ETDRS standards. The same applied for all participating photographers in the study centers. Optical coherence tomography (OCT) scans were neither adequate nor possible. Most participating centers had no OCT device, and OCT scans are more useful to measure changes in preexisting macular thickening.
Primary and Secondary Endpoints
Detection of CSME in at least one eye was defined as the primary endpoint. Both eyes were graded at each visit. Following detection of CSME in the central reading center, its occurrence was immediately reported and the patient was appropriately treated by laser and excluded from further follow-up.
Secondary objectives were the development of neovascularization elsewhere or at the disk, changes in severity of diabetic retinopathy according to the ETDRS severity scale [25] , the course of best corrected visual acuity, and contrast sensitivity as well as cataract formation measured by the Lens Opacity Classification System II.
Statistical Analysis
The statistical evaluation was based on a group sequential design with one interim and a final analysis. Using the O'BrienFleming approach and the Lan-De Mets ␣ -spending function methodology in the primary analysis, the single significance levels for an overall level of ␣ = 0.05 are ␣ 1 = 0.0054 for the interim analysis and ␣ 2 = 0.0492 for the final analysis. This report pre sents the results of the final analysis.
As in the O'Brien-Fleming approach, the final analysis keeps close to the overall significance level and has approximately the same power as a fixed-sample design, a fixed-sample approach was applied for sample size and power calculation. The effect size estimation was based on expert ratings from experienced ophthalmologists. It was assumed that we had a 62% event-free survival in the placebo group after 2 years and a 75% event-free survival in the treatment group. Given these assumptions and accounting for a 20% rate of nonevaluable patients, a required sample size of n = 260 recruited patients per group was calculated, providing 80% power of significantly detecting treatment differences in the primary analysis. Finally, slightly fewer patients have actually been recruited. Recalculation of the power, however, showed that it still was acceptable, amounting to 75%.
The primary endpoint was evaluated by a two-sided log-rank test, comparing the two treatment groups in an intention-to-treat approach (ITT). This particular hypothesis test provides confirmatory statistical evidence and constitutes the primary study result. Further supplementary analyses of the primary endpoint were performed, including Kaplan-Meier plots, a corresponding per-protocol analysis, and confidence interval (CI) estimation of the hazards ratio (HR) between the two treatment groups. Proportional hazard assumptions were verified using the GrambschThernau residual-based test. Secondary endpoints were evaluated, comparing means and proportions of the parameters given above between treatment groups with Student's t test and the 2 test, respectively. Bonferroni adjustment was applied to prevent type I error enhancement due to multiplicity.
Beyond analyses of primary and secondary endpoints, exploratory analyses were performed. The homogeneity of the treatment groups was checked with regard to demographic and relevant pretreatment data. Further exploratory analyses comprised evaluation of safety data, subgroup analyses, and multivariate analyses of the time to CSME development.
Statistical analyses were performed using SAS software (Version 9.1.3 for Windows, SAS Institute Inc., Cary, N.C., USA). In 
Withdrawal
All subjects were free to withdraw from this trial at any time, for any reason, specified or unspecified and without impact on their future treatment. Reasons for withdrawal are summarized in table 1 .
Results
Baseline Characteristics ( table 2 ) and Main Efficacy Results
All outcome assessments were performed by masked examiners. Of all 467 patients, 235 were randomized into the treatment group and 232 into the placebo group. In the treatment group, 101 patients (43.0%) were male and 134 female (57.0%), versus 94 (40.5%) and 138 (59.5%) in the placebo group. Mean age was 58.0 years in the treatment group and 57.9 years in the placebo group. Best corrected visual acuity over all patients measured with ETDRS letters (both eyes) was 108.9 in the treatment group and 106.9 in the placebo group at visit 1 (p = 0.0991) and remained unchanged until the final visit (107.9 vs. 104.6, p = 0.1464).
Mean HbA1c level was 8.1 ( 8 1.32 SD), with no significant differences seen following randomization at study entry when comparing the treatment group and placebo group. HbA1c values remained constant over time in all randomization strata. In the treatment and placebo groups, 84 (35.7%) versus 86 (37.1%) patients had IDDM and median duration of diabetes was 9.3 versus 9.0 years, respectively. For rates and reasons for study discontinuation, see table 2 .
At baseline, the degree of retinopathy did not significantly differ between treatment groups (p = 0.4342). Subsequently, the degree of retinopathy deteriorated in the placebo group with borderline significance (p = 0.0708) whereas it remained constant over time in the treatment group. On visit 3, significant differences in the degree of retinopathy emerged between the two groups (p = 0.0311). On visits 4, 5 and 6, however, the degree of retinopathy did not show any differences between groups anymore. A more detailed description of the participants, randomization and reasons of withdrawal is shown in figure 1 . ( table 3 ) Apart from IDDM, the most common concomitant conditions were hypertension (62.5%), coronary artery disease (8.6%), ischemic cardiomyopathy (7.5%), and dyslipidemia (7.1%). Other conditions were documented in less than 6% of the ITT population. In total, 463 patients treated with an ITT approach (99.1%) were taking a concomitant medication during the trial. Most prevalent concomitant medications, except those used for the treatment of diabetes, were enalapril maleate (27.4%), indapamide (19.3%), and acetylsalicylic acid (12.2%).
Comorbidity and Need for Medication Emerging during Therapy
Primary Endpoint
Concerning the primary endpoint, i.e. the cumulative CSME probability, the study provided a negative result: within the total observational period, 26/235 patients of the treatment group and 30/232 patients of the placebo group developed CSME. Confirmatory ITT analysis of the primary endpoint revealed no statistically significant difference between the two groups (logrank test, p = 0.7108, HR = 0.9057 with CI = 0.5355-1.5317). Median follow-up was identical in the two groups (2.00 years).
Univariate Predictors of CSME Development ( table 4 )
Looking at all randomized patients (n = 467), 411 patients did not develop CSME during the follow-up, while CSME was observed in 56 patients. Gender, HbA1c, body weight, body mass index, arterial hypertension, duration of diabetes, age and degree of retinopathy were no significant predictors of CSME development. Diabetes treatment (IDDM vs. NIDDM) turned out to be the only baseline covariate with a significant predictive capacity for CSME development (HR = 2.025, CI = 1.199-3.421, p = 0.0083).
Multivariate Analysis of CSME Development
The time to CSME development was modeled in a multivariate approach using the baseline covariates gender, diabetes treatment, HbA1c, body weight, body mass index, arterial hypertension, duration of diabetes, age, degree of retinopathy and treatment with ALA versus placebo. Except for diabetes treatment, none of the covariates proved to significantly influence CSME development. In the full model including all above covariates, the HR of IDDM versus NIDDM was 2.691 (CI = 1.469-4.929, C oncomitant medication such as acetylsalicylic acid (up to 500 mg/day), antihypertensives and diuretics were permitted as long as such treatments had been applied for at least 3 months, were to be continued for the duration of the clinical trial, and the patient met the inclusion criteria. p = 0.0013). IDDM increases the risk of developing CSME by a factor of 2.691 compared to NIDDM. The only relevant covariates, diabetes treatment and HbA1c (i.e. the covariates determining the randomization strata), and (randomized) treatment with ALA versus placebo were included in a reduced model. The reduced model allows for estimation of the adjusted treatment effect that results if the possible confounders, diabetes treatment and HbA1c, are kept constant. The adjusted HR of ALA treatment versus placebo amounts to 0.911 (CI = 0.539-1.541, p = 0.7276), indicating that active treatment does not significantly influence the time to CSME development. In further model-based analyses, it was investigated whether ALA treatment possibly shows interaction effects with baseline covariates. Interaction tests did not yield any positive results, indicating that the treatment effect was independent of baseline covariates, i.e. there was a null effect. ( table 5 ) Exploratory post-hoc analyses were performed in order to investigate whether ALA treatment might have a positive impact on the time to CSME development in certain subgroups of patients. In none of the subgroups did a significant treatment effect emerge. Moreover, no systematic pattern became apparent that might possibly have indicated a slight trend towards a beneficial treatment effect, e.g. in 'high-risk' subgroups of patients.
Subgroup Analyses
Safety Results
During the trial, 109 (46%) subjects of the ALA group and 112 (48%) subjects of the placebo group reported TEAEs. Most frequently occurring events were infections, metabolism and nutrition disorders, vascular disorders, cardiac disorders and nervous system disorders.
Comparing the ALA and the placebo group, TESAEs were reported by 9% versus 10% of subjects. TEAEs in 10 versus 4 subjects were considered to be related to the trial treatment; 11 subjects in both groups reported events of severe intensity, 4 versus 2 terminated the trial prematurely due to TEAEs, death (SAEs) occurred in 2 versus 3 subjects.
Conclusions
Diabetes increases oxidative stress, which is postulated to play an important role in the development of its microvascular complications [27] , such as retinopathy and macular edema, a potentially sight-threatening condition. In rats, ALA has been shown to prevent microvascular damage by normalizing pathways downstream of mitochondrial overproduction of reactive oxygen species and to preserve pericyte coverage of retinal capillaries, which may provide additional endothelial protection [16] . Others described beneficial effects on diabetic retinopathy via inhibition of accumulation of oxidatively modified DNA and nitrotyrosine [17] . Therefore, we assumed that supplementation with antioxidants such as ALA as an adjunct therapy may help to reduce the risk of visual loss in diabetic humans with NPDR.
For the present trial, we deliberately selected a highrisk population of IDDM patients with NPDR and microalbuminuria as especially the latter factor is known as a strong predictor of the development of microvascular and macrovascular complications [28] and assumed that this population may be suitable to detect potential protec- tive effects of our study medication. The Wisconsin data on the risk of developing macular edema [29] were based on HbA1c levels beyond 10%. In our study, we aimed at an average HbA1c level of 8%. However, we observed that ALA at the dose of 600 mg/day provided no significant protective effect on the occurrence of CSME. Differences in the level of retinopathy as seen during the first followup visits can be neglected, as all patients included presented with very mild NPDR and low retinopathy levels. Mild changes in the retinopathy level as seen in the placebo group have no clinical relevance either. No differences between the placebo and the treatment group concerning retinopathy levels were noted later on during the trial. A number of clinical trials, such as the ALADIN (I, II, and III), SYDNEY (I and II), and ORPIL, using ALA have been undertaken in diabetic patients to treat symptomatic diabetic peripheral neuropathy [30] [31] [32] [33] [34] [35] [36] using oral ALA supplements from 600 up to 1,800 mg/day. ALA was administered both intravenously at doses of 600-1,200 mg/day for up to 3 weeks, sometimes combined with prolonged administration of additional oral medications [30] [31] [32] [33] [34] [35] [36] [37] . Some of these reports described less symptoms of peripheral neuropathy [30, [34] [35] [36] , while others noted no clinically meaningful effect compared with placebo [32] . The fact that some positive results have been reported in diabetic neuropathy following ALA treatment but not in the prevention of diabetic macular edema may point to different pathomechanisms, and suggests that neuroglial damage is not an early event in diabetic macular edema formation while the breakdown of the bloodretinal barrier is the predominant causative mechanism. An improvement in insulin sensitivity in IDDM patients following the oral administration of ALA was also described [33] .
The observations described in the present clinical trial on human diabetic patients stand in contrast to previously reported findings in rats [16, 17] . However, in both animal studies, much higher ALA concentrations of 60 mg/kg [16] and 400 mg/kg body weight were administered over a period of 30 versus 44 weeks. One may conclude that the dosage of 600 mg/day in an adult (7.5 mg/ kg body weight in an 80-kg adult) as in our study may not have been high enough to exert a permanent effect on the human retina. No upper limit for ALA intake in humans has been established yet. In contrast, safety levels have been described for animals with pronounced species-dependent differences, showing that rats appear to be far more tolerant than many other species, such as dogs (LD 50 for dogs 400-500 mg/kg [36] vs. 1 2,000 mg/kg for rats [37] ). Some groups reported that an oral dose of 600 mg once daily appeared to provide the optimum risk-tobenefit ratio [38] . Our daily dosage of 600 mg/day was within the range of ALA dosages reported in the literature and could be considered safe.
One may suggest that 2 years' ALA administration was too short. In published clinical trials, the duration of oral ALA supplementation at a dose of 600 mg/day ranged from 4 weeks [33] to 2 years (combined with an initial intravenous injection of 600 mg for 3 days in the study by Reljanovic et al. [31] . In similar ophthalmological trials, such as the CALDIRET study [39] , a follow-up of 5 years was eventually found to be too long because the final result was predictable already after 2 years.
One may criticize that imaging techniques, such as OCT, were not part of the protocol of this trial. This is due to the fact that OCT was not available at all study centers, especially in Eastern Europe. However, according to the ETDRS protocol, the gold standard for the first detection of macular edema is stereoscopic photography, as done in this trial.
In summary, antioxidants such as ALA have become popular in different medical fields. While a positive effect in the treatment of diabetic patients using the dosage of 600 mg/day appears to be beneficial for neuropathy, no protective effect regarding the development of macular edema, another microvascular complication in diabetes, was seen in high-risk IDDM patients using the same dosage. Therefore, regular ophthalmological surveillance and interdisciplinary cooperation remain mandatory.
